Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.42 |
| ▸ | AKT1 | P31749 | 4/20 | 0.42 |
| ▸ | MTOR | P42345 | 4/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3287154 | 0.87 | MAPT (0.61) | CYP1A2CYP2D6MAPTCRHBPCRHR2 | |
| SCHEMBL13929506 | 0.84 | KMT2A (0.50) | CYP1A2CYP2D6MAPTCRHBPCRHR2 | |
| SCHEMBL6258232 | 0.82 | CRHBP (0.56) | CYP1A2CYP2D6MAPTCRHBPCRHR2 | |
| SCHEMBL4442165 | 0.81 | LGMN (0.42) | MAPTPIK3CAAKT1MTORCDK1 | |
| SCHEMBL14024999 | 0.78 | MAPT (0.56) | CYP1A2CYP2D6MAPTCRHBPCRHR2 | |
| SCHEMBL23299956 | 0.78 | KMT2A (0.47) | MAPTCRHBPCRHR2KMT2AATR | |
| SCHEMBL23275300 | 0.78 | HTT (0.42) | CYP1A2CYP2D6MAPTCRHBPCRHR2 | |
| SCHEMBL23876040 | 0.78 | KMT2A (0.47) | MAPTCRHBPCRHR2KMT2AATR | |
| SCHEMBL23274730 | 0.78 | HTT (0.42) | CYP1A2CYP2D6MAPTCRHBPCRHR2 | |
| SCHEMBL23274729 | 0.78 | HTT (0.42) | CYP1A2CYP2D6MAPTCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150545-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | AstraZeneca AB (SE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| WO-2008132505-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008132505-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | EPHB4, EPHB6, EPHB1 | CYP1A2 1950/4885CYP2D6 509/4885MAPT 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.